ResMed
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, ResMed sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
ResMed: 25 sponsored US clinical trials, 1 recruiting.
ResMed sponsors 25 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 20 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obstructive Sleep Apnea, with 2 trials.
Top-decile sponsor footprint
ResMed ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
20 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
ASV Therapy for Insomnia
NCT07011966
Oran Park Mask External Clinical Study (3) Marketing Claims Study
NCT06079866
Whitsundays (Nasal) Mask Take Home Study (90 Days)
NCT06036329
A Preference Study of Two Pneumatic Compression Devices for Patients With Lower Limb Lymphedema
NCT05485454
Safety and Feasibility of a Novel Device for Assessing Respiratory Function in Children
NCT04873193
Nebula Study - Screener Apps and HSAT vs. PSG Comparison
NCT04597749
Evaluating the Efficacy of PAP Therapy for Treating OSA in the Home Environment
NCT04744038
Compact Pneumatic Compression Device for Patients With Lymphedema
NCT04226287
Evaluation of a Portable Oxygen Concentrator During Ambulation for Patients Who Require Supplemental Oxygen (POC-LEAN)
NCT04107493
Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients
NCT03851094
Validation of ApneaLink Air Home Sleep Testing in the Diagnosis of Obstructive Sleep Apnea in Adolescent Children
NCT03748771
Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)
NCT03513068
ApneaLink Air Home Sleep Testing (HST) Device Validation Study
NCT03470493
Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
NCT03195660
Respiration Rate Monitoring in COPD Patients
NCT03030313
Astral VAPS AutoEPAP Clinical Trial
NCT02683772
Reassure Remote Respiration Monitoring in Heart Failure Patients
NCT02624739
CPAP vs ASV for Insomnia
NCT02365064
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
NCT01953874
Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use
NCT01462084
Evaluation of Acclimate Feature for Positive Airway Pressure (PAP) Therapy
NCT01421654
Pediatric Nasal Mask Usability Study
NCT01154322
Complex Sleep Apnea Syndrome (CompSAS) Resolution Study
NCT00915499
GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes
NCT00509223
Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)
NCT00354614
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Therapeutic Areas
Where ResMed enrollment is open (later-stage tilt)
1 recruiting of 25 indexed (4% open); 20 completed (80%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Obstructive Sleep Apnea (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ResMed: open-pipeline peers nationwide
Peers matched on 25 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
ResMed sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Fisher and Paykel Healthcare · 4% recruiting · 25 trials
- Mesoblast · 4% recruiting · 25 trials
- Sangamo Therapeutics · 4% recruiting · 25 trials
- MedtronicNeuro · 4% recruiting · 51 trials
Related
What to do with this ResMed page
25 registered trials is a research-attention snapshot, not an endorsement of ResMed or any single study.
- 1 of ResMed's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obstructive Sleep Apnea is the condition ResMed studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obstructive Sleep Apnea trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ResMed pipeline card: 25 registered trials from official public datasets.Report a data error.